Mainline Biosciences

Based in Zhongshan, China, and founded in 2022, Mainline Biosciences is a biotechnology company focusing on peptide innovative drug 2. 0. It has branches in Shanghai and the United States to jointly promote the global peptide drug development process. The clinical development team has years of experience in managing pharmaceutical companies and has led the development and launch of major drugs such as Gleevec, Tasigna, Avastin, and Cabometyx.

In July 2024, Mainline Biosciences closed a venture funding from new investor Taikun Fund. The company's main business is to develop innovative peptide drug conjugates (PDCs) using its proprietary multifunctional peptide drug discovery and optimization platform to meet unmet clinical needs in the field of oncology. The company's independently developed products include MB0151, the first PDC targeting SSTR2 for advanced solid tumors, and an AI-enhanced peptide therapy pipeline designed for precise toxin delivery through computer-assisted peptide sequence engineering. Its products are used in the fields of cancer immunotherapy and targeted therapy.

The company generates revenue by licensing its PDC technology platform to pharmaceutical partners, collaborating on projects with global biotechnology companies, and advancing clinical-stage assets through strategic partnerships and government-funded oncology programs.